Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h01 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
06 mars 2023 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027
23 févr. 2023 07h14 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today...
Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results
21 févr. 2023 07h00 HE
|
Assertio Holdings, Inc.
Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for...
Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference
16 févr. 2023 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio to Participate in the 2023 SVB Securities Global Biopharma Conference
08 févr. 2023 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
17 janv. 2023 09h00 HE
|
Assertio Holdings, Inc.
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
09 janv. 2023 16h15 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 janv. 2023 16h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco
13 déc. 2022 14h07 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...